Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 3/20 | 0.32 |
| ▸ | EDNRB | P24530 | 2/20 | 0.31 |
| ▸ | EDNRA | P25101 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799872 | 0.87 | CNR2 (0.35) | CNR2GRM5 | |
| SCHEMBL2768617 | 0.83 | GRM5 (0.39) | GRM5POLB | |
| SCHEMBL1794725 | 0.76 | MAPK8 (0.35) | CNR2CTSAEDNRBEDNRANPC1 | |
| SCHEMBL1798770 | 0.71 | EDNRA (0.32) | CNR2CTSAEDNRBEDNRA | |
| SCHEMBL1801475 | 0.70 | CNR2 (0.34) | CNR2EDNRBEDNRANPC1RAB9A | |
| SCHEMBL1797443 | 0.66 | CMA1 (0.38) | GRM5NPC1RAB9ARXFP1POLB | |
| SCHEMBL1799689 | 0.61 | CTSK (0.36) | — | |
| SCHEMBL5126789 | 0.61 | CTSK (0.36) | CNR2NPC1RAB9ARXFP1HPGD | |
| SCHEMBL2768616 | 0.61 | MAPK8 (0.33) | EDNRAPOLB | |
| SCHEMBL15689096 | 0.60 | ADAM17 (0.41) | CTSANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163909-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7951838-B2 | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | BACE1, APP, BACE2 | CNR2 334/4885GRM5 466/4885CTSA 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.